I have read this before but rereading it realized a more fundamental flaw. The author built an amazing tool that's actually worth a lot of money, but not for patients or doctors! The healthcare data analytics industry would kill for a version of this tool done well. Pharma companies and consultants would pay tens of thousands (if not more) to access a tool like this that's kept up to date. He could have sold the IP and rhe data and the protocols (or get acquired) if he'd networked a bit more in this side. It's probably still not too late!